Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; sodium bicarbonate; pregelatinised maize starch; lactose monohydrate; iron oxide red; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; croscarmellose sodium; lactose monohydrate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril -

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

proficient rx lp - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 2.5 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see clinical studies (14.3) ]. ramipril is contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydra

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rebel distributors corp - ramipril (unii: l35jn3i7sj) (ramipril - unii:l35jn3i7sj) - ramipril 2.5 mg - ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low hdl levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). ramipril capsules are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insuf

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

camber pharmaceuticals - ramipril (unii: l35jn3i7sj) (ramipril - unii:l35jn3i7sj) - ramipril 1.25 mg - ramipril capsules, usp are indicated for the treatment of hypertension. they may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [see warnings and precautions ( 5.6 ) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical studies of ramipril, 11.0% wer

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

dispensing solutions, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 10 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in us clinical studies of ramipril 11% were ≥65 years of age while 0.2% were ≥75 years of age. no overall differences in effectiveness or safety were observed between

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [see  w a rnings and precautions (5.6) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical studies of ramipril, 11% were ≥65 ye